28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Memantine (Ebixa, Axura, Namenda, Akatinol) is a moderate-affinity, uncompetitive, voltage-dependent, NMDA-receptor antagonist with fast on/off kinetics that inhibits excessive calcium influx induced by chronic overstimulation of the NMDA receptor. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Effective interventions in diet, medications, biochemical exposures, psychological condition, pre-existing disease and lifestyle may decrease new incidence of AD. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Ankylosing spondylitis is associated with increased risk for vascular mortality. 5 key findings →
Design: cohort study Participants: 473 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Continued lithium treatment was associated with reduction of the rate of dementia to the same level as that for the general population. 3 key findings →
Design: cohort study Participants: 16,238 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Global concern on the potential impact of dementia is mounting. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Social activity is associated with a decreased risk of incident disability in activities of daily living, mobility, and instrumental activities of daily living, among community-dwelling older adults. 4 key findings →
Design: cohort study Participants: 954 Evidence: moderate
Full summary, score breakdown and related studies → Original source
NPS were observed to be highly prevalent in AD patients. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Coffee is the leading worldwide beverage after water and its trade exceeds US $10 billion worldwide. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Hearing aids may have a mitigating effect on trajectories of cognitive decline in later life. 2 key findings →
Design: cohort study Participants: 2,040 Evidence: moderate
Full summary, score breakdown and related studies → Original source
OHL was associated with greater risk of incident dementia in a multiethnic cohort. 4 key findings →
Design: cohort study Participants: 1,881 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Short-term mortality is increased in patients newly diagnosed with probable AD. 5 key findings →
Design: longitudinal study Participants: 327 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Diabetes mellitus may be associated with an increased risk of developing AD and may affect cognitive systems differentially. 5 key findings →
Design: cohort study Participants: 151 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A history of depression may confer an increased risk for later developing AD. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Recent studies have used non-invasive brain stimulation (NIBS) techniques, such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), to increase dorsolateral prefrontal cortex (DLPFC) activity and, consequently, working memory (WM) performance. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
We also identified several common challenges. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Between Jan 1, 2000, and Dec 31, 2016, of 63 038 019 individuals who were aged 65 years or older during the study period, we identified 1·0 million cases of Parkinson's disease and 3·4 million cases of Alzheimer's disease and related dementias based on primary and secondary diagnosis billing codes. 1 key finding →
Design: cohort study Participants: 19 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Strong conclusions remain elusive, although the weight of the evidence suggests an adverse association between PM2.5 and cognitive decline. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive impairment associated with aging is a serious and growing public health problem. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We reviewed epidemiological and experimental studies of female gonadal hormone replacement therapy (HRT) on cognitive function in post-menopausal women and carried out meta-analyses. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A case-control study was performed to determine the possible roles of various environmental factors, prior illnesses, drug use, and personal habits in the development of Alzheimer's disease. 4 key findings →
Design: case-control study Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Meta-analysis was used to examine pooled parameter estimates of 9 active compared with 6 control conditions of the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project at 6 months on caregiver burden and depressive symptoms. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Increased serum proinflammatory cytokines are associated with the presence of symptoms characteristic of sickness behavior, which are common neuropsychiatric features found in AD. 3 key findings →
Design: cohort study Participants: 300 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Linking detailed HCAP cognitive assessments to the wealth of available longitudinal HRS data on cognition, health, biomarkers, genetics, health care utilization, informal care, and economic resources and behavior will provide unique and expanded opportunities to study cognitive impairment and dementia in a nationally representative US population-based sample. 5 key findings →
Design: longitudinal study Participants: 3,496 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This review shows that communication skills training in dementia care significantly improves the quality of life and wellbeing of people with dementia and increases positive interactions in various care settings. 3 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →